Posaconazole Oral Suspension Suppliers & Bulk Manufacturers
Available Forms: Oral Suspension
Available Strengths: 40 mg/mL
Reference Brands: Noxafil(US & EU)
Category: Anti-fungal
Posaconazole oral suspension inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity. It offers broad-spectrum antifungal activity, improved absorption, and versatility for prophylaxis and treatment of invasive fungal infections. Benefits include effective coverage, convenient dosing, and high bioavailability for managing severe fungal diseases. Posaconazole Oral Suspension is available in Oral Suspension and strengths such as 40 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Posaconazole Oral Suspension is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Posaconazole Oral Suspension can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Posaconazole oral suspension is approved in the EU and US for prophylaxis and treatment of invasive fungal infections. In the EU, MSD’s Noxafil suspension is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data and biosimilarity assessments, with ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continual safety monitoring. For expert support with dossiers, regulatory submissions, and compliance, visit PharmaTradz. We help ensure smooth market entry and adherence to European and American standards, enabling effective management of fungal infections with posaconazole oral suspension.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Posaconazole is used to prevent and treat serious fungal infections in high-risk patients, especially those with weakened immune systems such as individuals with hematologic cancers or transplant recipients. It is effective against invasive aspergillosis, mucormycosis, and resistant Candida infections, and is often used when other antifungals are not tolerated or have failed.
Posaconazole contains the active triazole antifungal compound posaconazole. The formulation uses specific pharmaceutical excipients designed to enhance absorption in the digestive system and ensure stable systemic exposure.
The main trade name is Noxafil, widely used in the USA, EU, UK, and other international regions.
Noxafil is manufactured by Merck & Co. (MSD). Several GMP-certified global pharmaceutical manufacturers also produce generic posaconazole for different markets.
The generic name is posaconazole.
The primary brand name is Noxafil.
Posaconazole is manufactured in Merck’s regulated facilities in the USA and Europe, along with additional GMP-approved manufacturers that supply generic posaconazole for worldwide distribution.
Related Products
Naftifine Hydrochloride
Strength:
1 %, 2%
Form: Cream / Gel
Reference Brands: Naftin (USA), Xolafin (USA)
View Details
Sertaconazole Nitrate
Strength:
2 %
Form: Creams
Reference Brands: Ertaczo (USA), Zalain (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
